secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORASURE TECHNOLOGIES INC (OSUR)
CIK:        0001116463
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001193125-24-285106
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OraSure acquires Sherlock Biosciences for $5M upfront plus up to $20M milestones and royalties on CT/NG test
--------------------------------------------------------------------------------

- Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.
- Two milestone payments up to $20M aggregate tied to regulatory approval of Sherlock's CT/NG test.
- Quarterly mid-single-digit royalties on CT/NG test net sales through 2034.
- Sherlock becomes wholly owned subsidiary; convertible notes, preferred, and common stock receive allocated consideration.
- Stock options terminated without payment; financial statements to be filed by amendment within 71 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1116463/000119312524285106/0001193125-24-285106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1116463/000119312524285106/d884076d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-285106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer